3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Sarcoma
1
Dermatologic
1
Conditions
Colorectal Neoplasms
86
Colonic Neoplasms
32
Rectal Neoplasms
31
Neoplasms
24
Pancreatic Neoplasms
22
Stomach Neoplasms
20
Neoplasm Metastasis
20
Esophageal Neoplasms
20
Neuroblastoma
12
Glioma
11
Sarcoma
9
Glioblastoma
9
Small Cell Lung Carcinoma
8
Carcinoma, Non-Small-Cell Lung
8
Brain Neoplasms
8
Adenocarcinoma Of Esophagus
8
Rhabdomyosarcoma
7
Lung Neoplasms
7
Sarcoma, Ewing
6
Gliosarcoma
6
Esophageal Squamous Cell Carcinoma
6
Medulloblastoma
5
Central Nervous System Neoplasms
5
Breast Neoplasms
5
Parkinson Disease 4, Autosomal Dominant Lewy Body
4
Intestinal Neoplasms
4
Gastrointestinal Neoplasms
4
Digestive System Neoplasms
4
Digestive System Diseases
4
Adenocarcinoma
4
Interventions
Ipilimumab
98
pembrolizumab
84
Nivolumab
82
aldesleukin
51
Cyclophosphamide
49
Interleukin-2
38
fludarabine phosphate
31
Vemurafenib
31
Dacarbazine
31
dabrafenib
29
trametinib
28
Temozolomide
26
fludarabine
25
CTLA-4 Antigen
18
Bevacizumab
18
Radiosurgery
15
Paclitaxel
15
Carboplatin
14
encorafenib
13
binimetinib
13
Introns
13
talimogene laherparepvec
12
Radiotherapy
12
Interferon alpha-2
12
spartalizumab
11
cobimetinib
10
atezolizumab
10
sargramostim
9
peginterferon alfa-2b
9
montanide ISA 51
9
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Melanoma
×
Irinotecan
×
Clear all
NCT03009058
2024-11-25
MODULATE
Immodulon Therapeutics Ltd
Phase 1/2
Terminated
2 enrolled
7 charts